Outlook Therapeutics is gearing up for the U.S. launch of LYTENAVA™, its FDA-approved treatment for wet AMD, with the appointment of Kevin Lundquist as CFO. However, the company faces financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results